Skip to main content

Table 2 The equipment and medication for chronic respiratory diseases in PHC institutions

From: Current status of prevention and treatment of respiratory diseases in primary care in China: a cross-sectional study

Characteristic

Value

Equipment, No. (%)

 

 Spirometer

91 (63.2%)

 Number of nebulization equipment

 

  > 3

58 (40.3%)

  2–3

33 (22.9%)

  1

20 (13.9%)

  0

33 (22.9%)

 Nebulizer mask for children

97 (67.4%)

 Pulse oximeter

91 (63.2%)

 Hematology analyzer

113 (78.5%)

 X-ray apparatus

105 (72.9%)

 Oxygen therapy device

108 (75%)

 Size of the area for pulmonary function test

 

  ≥ 8 m2

72 (50%)

  < 8 m2 and > 0

8 (5.6%)

  0

64 (44.4%)

 Size of the area for nebulization

 

  ≥ 8 m2

77 (53.5%)

  < 8 m2 and > 0

8 (5.6%)

  0

59 (40.9%)

Medicine, No. (%)

 

 SAMA/SABA

116 (80.6%)

 LAMA/LABA

88 (61.1%)

 Combination low dose ICS -LABA

79 (54.9%)

 Theophylline

127 (88.2%)

 LTRA

72 (50%)

 Systemic corticosteroid

126 (87.5%)

 Antibiotics

131 (91%)

 Traditional Chinese medicine

126 (87.5%)

  1. SAMA short-acting muscarinic antagonist, SABA short-acting beta2 agonist, LAMA long-acting muscarinic antagonist, LABA long-acting beta2 agonist, ICS inhaled corticosteroids, LTRA leukotriene receptor antagonist